LifeStance Health Group, Inc. (NASDAQ:LFST) Insider Ujjwal Ramtekkar Sells 16,000 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) insider Ujjwal Ramtekkar sold 16,000 shares of the stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $5.94, for a total value of $95,040.00. Following the sale, the insider now owns 113,435 shares in the company, valued at approximately $673,803.90. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

LifeStance Health Group Price Performance

LFST stock traded down $0.18 during mid-day trading on Thursday, hitting $5.42. The company had a trading volume of 1,827,471 shares, compared to its average volume of 1,603,911. The company has a 50-day moving average price of $6.19 and a 200 day moving average price of $7.05. LifeStance Health Group, Inc. has a 12-month low of $4.64 and a 12-month high of $8.61. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -20.85 and a beta of 1.22. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. William Blair restated an "outperform" rating on shares of LifeStance Health Group in a research note on Friday, February 28th. UBS Group raised LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 price target on the stock in a report on Tuesday, May 27th. Canaccord Genuity Group assumed coverage on LifeStance Health Group in a research note on Thursday, April 3rd. They issued a "buy" rating and a $8.00 price objective for the company. Finally, KeyCorp assumed coverage on LifeStance Health Group in a research report on Tuesday, April 8th. They set an "overweight" rating and a $9.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, LifeStance Health Group currently has a consensus rating of "Moderate Buy" and an average price target of $8.50.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds have recently made changes to their positions in LFST. Blue Trust Inc. raised its holdings in shares of LifeStance Health Group by 124.4% during the 4th quarter. Blue Trust Inc. now owns 3,828 shares of the company's stock worth $27,000 after acquiring an additional 2,122 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in LifeStance Health Group during the first quarter valued at $31,000. Xponance Inc. purchased a new position in shares of LifeStance Health Group in the 1st quarter worth $69,000. Ameriprise Financial Inc. purchased a new position in shares of LifeStance Health Group in the 4th quarter worth $87,000. Finally, Kapitalo Investimentos Ltda bought a new stake in shares of LifeStance Health Group in the 1st quarter worth about $87,000. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.